KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
Go back to KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference| (NASDAQ: KALV) | Delayed: 27.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.00 | 52 Week High | $ | |||
| Open | $27.00 | 52 Week Low | $ | |||
| Day High | $27.00 | P/E | N/A | |||
| Day Low | $27.00 | EPS | $ | |||
| Volume | 5,139 | |||||
